Skip to Main Content
MENU
Careers

We’re always seeking talented people who share our vision. Click here to explore opportunities in a variety of disciplines across the globe.

See More >
Leadership Blogs

Get to know our leaders. Read their unique perspectives on how they are working to change the trajectory of health.

See More >
Generation Care™

We’re committed to showing the heart of the caregiver’s experience and providing the kind of support and information that will make a difference.

See More >
Patient Engagement

Janssen partners directly with patients and caregivers as we develop medicines, improve clinical trials, and create educational materials and support programs.

See More >
Research & Development

Our research pipeline is rich with transformational science reflecting our unique approach to innovation.

See More >
R&D Data Science

Using data science and digital health to reimagine the discovery and development of medicines to advance our mission of bringing transformative therapies to patients.

See More >
  • An African American couple dance cheek to cheek
    An African American couple dance cheek to cheekAn African American couple dance cheek to cheek

    Courageously
    Taking on
    Age-related MacularAge-related
    Macular
    Degeneration (AMD)Degeneration
    (AMD)

Item 1 of 1

AMD is the leading cause

of vision loss among older adults1

As of 2020, ~200 million people

worldwide are affected by AMD2

AMD is the deterioration of the retina and choroid that leads to a substantial loss in sharpness of vision.3 Yellow deposits under the retina are called drusen, and having them may increase a person’s risk of developing AMD.4

AMD is classified as early AMD, intermediate AMD, and advanced AMD. A large number of drusen being present in the eye is an important indicator of early AMD.5

An Asian woman holds a cup while looking out a window

Janssen is exploring novel class therapies, including a gene therapy for the treatment of age-related macular degeneration

“

Investigational programs facilitated by Johnson & Johnson Innovation, and our in-house discovery team, have the potential to transcend the standard of care in retinal disorders.

-Wai Wong MD, PhD – Vice President Retinal Disease – CVMR Discovery SSF

”

See our investments in gene therapy and treatments for AMD

View our research
A scientist wearing a hairnet and mask works in a lab
Hide referencescollapse

  1. Age-related Macular Degeneration. National Eye Institute. National Institutes of Health. Updated June 22, 2021. Accessed August 3, 2021. https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/age-related-macular-degeneration

  2. Stahl A. The diagnosis and treatment of age-related macular degeneration. Dtsch Arztebl Int. 2020;117(29-30):513-520.

  3. Foundation of American Society of Retina Specialists. Accessed September 29, 2021. https://www.asrs.org/patients/retinal-diseases/2/agerelated-macular-degeneration

  4. Porter D. What are drusen? American Academy of Ophthalmology. Accessed September 29, 2021. https://www.aao.org/eye-health/diseases/what-are-drusen#:~:text=Drusen%20are%20yellow%20deposits%20under,are%20different%20kinds%20of%20drusen

  5. Elshatory YM. Age-related macular degeneration. EyeWiki. Accessed September 29, 2021. https://eyewiki.org/w/index.php?title=Age-Related_Macular_Degeneration&oldid=71726